Main Findings
Our results support that sentinel lymph node biopsy is feasible,
reproducible, and sensitive without affecting cancer-specific outcomes
when implemented at a non-specialized center for Type I endometrial
cancer. SLN mapping alone accurately identified at least one lymph node
in 95.4% of patients with endometrial cancer at our institution and our
overall bilateral SLN mapping rate reached 80% by the end of our study
period.